Skip to content

Effectiveness of Smartphone Application for Adherence Support (Vuka+)

Effectiveness of Smartphone Application (Vuka+) for Adherence Support in Adolescent Girls and Young Women -Type I Hybrid Implementation Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06897059
Enrollment
330
Registered
2025-03-26
Start date
2022-12-15
Completion date
2024-11-08
Last updated
2025-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adherence, Medication, Smartphone Application

Keywords

PrEP, HIV, smartphone

Brief summary

This is a Type I Hybrid effectiveness-implementation trial to evaluate an HIV Pre-Exposure Prophylaxis (PrEP) medication adherence, persistence and social support app (Vuka+) for adolescent girls and young women (AGYW) in South Africa. This 6-month, 2-arm effectiveness and implementation trial (standard of care \[SOC\] vs. intervention app) will assess acceptability, feasibility and effectiveness. In addition, we will gather information on intervention delivery and barriers and facilitators for real-world delivery to inform future implementation and scale up.

Detailed description

We will recruit 330 AGYW, aged 15-24 from the surrounding community, PrEP clinics and service providers in Cape Town, South Africa. If AGYW qualify for enrollment, they will be offered daily Truvada as PrEP. Participants will then be randomized 1:1 at baseline to SOC counselling and the Vuka+ intervention app or SOC counselling only (control). All participants will receive their regularly scheduled PrEP clinical care visits. At baseline, 1-, 3- and 6-month follow-up visits, participants will complete biobehavioral surveys, undergo HIV testing and pregnancy testing, and provide a urine (month 1 and 6) and DBS sample (months 1, 3 and 6) for tenofovir assessment. Intervention arm participants will also have the following study activities: install the intervention app on their phones at baseline study visit and be asked to use the intervention app for at least 5-10 minutes daily for 6 months. During this time, they will be prompted by the app to complete daily activities or health and wellness readings and to complete a weekly brief assessment related to their PrEP use. At follow-up study visits, intervention arm participants will complete an additional set of questions evaluating their app use experience and a subsample of participants will complete an in-depth qualitative exit interview to assess their app use experience, acceptability of the intervention and their evaluation of the app's content.

Interventions

OTHERVuka+ application

The Vuka+ smartphone app included PrEP daily reminders, tracking for pill taking, resources for sexual reproductive health including quizzes and articles, and chat access to other Vuka+ users and medical expert.

Sponsors

CONRAD
CollaboratorOTHER
Desmond Tutu Health Foundation
CollaboratorOTHER
Florida State University
CollaboratorOTHER
University of North Carolina, Chapel Hill
CollaboratorOTHER
United States Agency for International Development (USAID)
CollaboratorFED
Gilead Sciences
CollaboratorINDUSTRY
Old Dominion University
CollaboratorOTHER
Eastern Virginia Medical School
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
15 Years to 24 Years
Healthy volunteers
Yes

Inclusion criteria

* Assigned female at birth * Age 15-24 years * Healthy and weight at least 35kg * Sexually active (had a male sexual partner in the past 6 months) * Consistent access to a smartphone * HIV-negative (clinic test) * PrEP naive or no PrEP use in the past 6 months * Eligible to start oral PrEP

Exclusion criteria

* Unable to currently start PrEP * Abnormal laboratory, medical, physical, or social finding which could impact study participation, by investigator discretion * Unwilling or unable to provide informed consent * Participating in another PrEP trial * Unwilling to provide at least 2 forms of contact for follow-up * Taking renal toxic medications * Sexual partner known to be HIV-positive

Design outcomes

Primary

MeasureTime frameDescription
PrEP adherence3 monthsAdherence to PrEP was measured by tenofovir diphosphate (TFV-DP) concentrations in dried blood spots (DBS)

Secondary

MeasureTime frameDescription
Vuka+ app acceptability6 monthsQuestionnaires and in-depth interviews were used to assess the acceptability of the smartphone app in the study population.
Vuka+ app usability6 monthsQuantitative self-reported usability measures (validated scales) were asked at follow-up visits.

Countries

South Africa

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026